AbbVie, Astellas Pharma, and AstraZeneca announced partnerships for the Linzess drug's sales and development in various markets.

The entities involved

• AbbVie →

  pharmaceutical company

  • MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
  • AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48
• Astellas Pharma →

  company

  Nothing else this week.

• AstraZeneca →

  British-Swedish pharmaceutical company

  • AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
  • Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.Sat 18:52

Related events

• Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.Aug 28
• AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.Sep 4
• AbbVie and Novo Nordisk are high-profile pharmaceutical stocks serving over 45 million people worldwide, with Cor acting as a significant distribution partner.Sep 10
• Chinese pharmaceutical companies are investing heavily in novel technologies while AstraZeneca confirms its Cambridge headquarters and CEO.Jul 27
• Iambic Therapeutics announced multiple new partnerships, including collaborations with Jazz Pharmaceuticals and AbbVie, and received backing from Qatar Investment Authority and Nvidia.Sep 22